Glenmark expects 10-12% sales growth in FY22, anticipates value unlock of its RD business

Sale of anti-COVID drug Fabiflu and other products fire Q1 revenues; the company spends little over $100 million annually on innovation RD business, bigger than most of its peers, developing a potential pipeline of drug assets

from Moneycontrol Business News https://ift.tt/3i62RHe